Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

490 resultsPage 28 of 41, newest first
  1. Sustainability23家锂电企业齐聚天府新区 国内首个锂电全链条ESG协作机制启动格隆汇9月5日｜据每经，9月3日，第四届零碳协同创新大会在四川天府新区隆湖畔顺利举行。会上，由天齐锂业牵头组建、覆盖锂电池全价值链的“可持续锂电池行业工作组”正式启动，这是中国锂电池行业首个覆盖上中下游全链条的ESG与可持续发展行业协作机制。工作组将主要聚焦欧盟新电池法规与电池护照技术规范互认、本土碳足迹数据建设、供应链可信追溯与安全数据协同、行业可持续叙事与国际合作四大方向，致力于减少重复审核与...
  2. SustainabilityGeopolymer Concrete Market - Global Forecast to 2036 As Low-Carbon Construction Drives 10.8% Market GrowthThe global geopolymer concrete market is projected to grow from USD 8.62 billion in 2026 to USD 24.03 billion by 2036, registering a 10.8% CAGR. Growth is driven by demand for sustainable, low-carbon construction materials, stricter environmental regulations and expanding infrastructure investment. Fly ash leads by raw material, while precast concrete is forecast to grow fastest. Infrastructure remains the largest application, and Asia-Pacific dominates the market, with North America and Europe also showing strong growth potential.
  3. SustainabilityMAISON & OBJET PARIS 2026: Gurunavi präsentiert in Paris Live-Vorführungen der über 1000 Jahre alten „Magewappa"-Tradition sowie 40 japanische Holzprodukte, die zur Dekarbonisierung beitragen und ESG-Ziele unterstützen– Yoshimasa Shibata, einer von nur 16 zertifizierten Meistern des Odate-Magewappa-Handwerks in Japan, wird in Paris Live-Vorführungen zum präzisen Biegen mit heißem Wasser sowie zum Vernähen mit Wildkirschrinde geben – TOKIO, 4. September 2026 -- Gurunavi, Inc. gab bekannt,...
  4. IndustrialPAC Machinery to Showcase Packaging Equipment, Sustainable Materials, and Flexible Packaging Solutions at PACK EXPO International 2026PAC Machinery will showcase packaging automation, sustainable materials, and flexible packaging solutions at PACK EXPO International 2026.
  5. FinanceCMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)SHENZHEN, CHINA - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA for indication AD has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which effectively shortened the product's review process and accelerated the marketing approval for the AD indication. From “First Topical JAK Inhibitor” to Indication Expansion, Lumirix® Continues to Deliver Clinical Value In January 2026, Lumirix® was approved for marketing by the NMPA, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo. The approval of this NDA for the additional indication of AD offers a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*. Previously, Lumirix® achieved positive results in a randomized, double-blind, placebo-controlled phase III clinical trial in China for mild to moderate AD: · Robust Efficacy: Lumirix® successfully met its primary endpoint— a significantly higher proportion of patients treated with Lumirix® achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with Lumirix® was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). · Favorable Safety Profile: the severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, Lumirix® was safe and well-tolerated. *Based on Phase III clinical data from China and overseas. Building the AD “treatment + care” Solution to Strengthen Dermavon's Skin Health Layout AD is a chronic, recurrent and inflammatory dermatologic disease. According to CIC Report, there were over 54 million AD patients in China in 2024[1]. To address the needs of AD patients from treatment to daily care, Dermavon has built a comprehensive “treatment + care” solution: · Topical formulation: Lumirix® (mild-to-moderate AD) – Marketed in China · Injectable biological agent: Comekibart Injection (moderate-to-severe AD) – Under NDA review in China · Oral small molecule targeted drug: CMS-D001 (moderate-to-severe AD) – Phase II clinical trial · Daily repair: Heling Soothing Product Series – Marketed in China Simultaneously, the indication expansion of Lumirix® will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health. About AD AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream is a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, as well as the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate[3,4]. On 2 December 2022, Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream, obtaining an exclusive license to develop, register and commercialize the product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the product in the Territory. Dermavon has sublicensed the relevant rights for the product outside of Mainland China to the Group (excluding Dermavon). About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. References 1. China Insights Consultancy’s industrial report 2. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib 3. The EMA approval information for vitiligo indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 4. The EMA approval information for AD indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/opzelurar-ruxolitinib-cream-becomes-first-steroid-free-topical CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: [email protected]: https://web.cms.net.cn/en/home/
  6. SaaSFormerraFormerra Receives 2026 Eaton Supplier Excellence AwardROMEOVILLE, IL, Sept 4, 2026 - Formerra, a leader in performance materials distribution, was recognized for its partnership at Eaton's 2026 Global Supplier Conference & Excellence Awards, held Thursday, August 27 in Beachwood, Ohio. Formerra was one of only 30 suppliers recognized with Eaton's Supplier Excellence Award from among the company's global network of more than 30,000 supplier partners. Eaton grants the Supplier Excellence Award to suppliers that exceed expectations through exceptional performance, innovation, and contributions to growth. Formerra serves as Eaton's preferred plastics distribution partner, a role built through disciplined execution and engagement across Eaton's corporate organization and manufacturing sites. While the partnership began over 15 years ago in North America, it now extends into Asia, Europe, and the Middle East, where Formerra recently established dedicated logistics and warehousing capabilities in Dubai to support Eaton's expansion in the region. Formerra has broadened its support, extending beyond polymer distribution in response to Eaton's dynamic requirements. The scope now covers thermoset materials, finished goods distribution, supply chain optimization, global logistics, and technical application support. "Eaton holds its supply base to a high standard, and this recognition reflects work our teams do every day across three continents," said Tom Kelly, Chief Executive Officer, Formerra. "Our people earned it by understanding how Eaton operates, anticipating needs, and solving problems before they reach a production line. The relationship between Formerra and Eaton offers strengthened supply resiliency, reduced supply chain risk, vendor consolidation, and improved operational efficiency as Eaton continues to pursue global growth. Caption: (L to R) Mike Hibbs, Global Category Manager, Eaton; Susan Logue, Sr. Key Accounts Manager, Formerra; Tom Kelly, CEO, Formerra Key Details: Formerra received the Supplier Excellence Award at Eaton's annual supplier conference. Formerra was one of 30 suppliers recognized from a global network of more than 30,000. Formerra serves as Eaton's preferred plastics distribution partner across North America, Asia, Europe, and the Middle East. Formerra has established warehousing capabilities in Dubai to support Eaton's regional operations. Support extends beyond plastics distribution into thermoset materials, finished goods distribution, supply chain optimization, and global logistics. About Formerra Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com. Contact Media Relations Global & Americas: Jackie Morris Email: [email protected] Phone: 630.849.3620 SOURCE: Formerra
  7. FinanceCMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)SHENZHEN, CHINA - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA for indication AD has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which effectively shortened the product's review process and accelerated the marketing approval for the AD indication. From “First Topical JAK Inhibitor” to Indication Expansion, Lumirix® Continues to Deliver Clinical Value In January 2026, Lumirix® was approved for marketing by the NMPA, becoming the first topical JAK inhibitor approved in China for the treatment of vitiligo. The approval of this NDA for the additional indication of AD offers a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*. Previously, Lumirix® achieved positive results in a randomized, double-blind, placebo-controlled phase III clinical trial in China for mild to moderate AD: · Robust Efficacy: Lumirix® successfully met its primary endpoint— a significantly higher proportion of patients treated with Lumirix® achieved IGA (Investigator's Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with Lumirix® was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). · Favorable Safety Profile: the severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, Lumirix® was safe and well-tolerated. *Based on Phase III clinical data from China and overseas. Building the AD “treatment + care” Solution to Strengthen Dermavon's Skin Health Layout AD is a chronic, recurrent and inflammatory dermatologic disease. According to CIC Report, there were over 54 million AD patients in China in 2024[1]. To address the needs of AD patients from treatment to daily care, Dermavon has built a comprehensive “treatment + care” solution: · Topical formulation: Lumirix® (mild-to-moderate AD) – Marketed in China · Injectable biological agent: Comekibart Injection (moderate-to-severe AD) – Under NDA review in China · Oral small molecule targeted drug: CMS-D001 (moderate-to-severe AD) – Phase II clinical trial · Daily repair: Heling Soothing Product Series – Marketed in China Simultaneously, the indication expansion of Lumirix® will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health. About AD AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream is a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, as well as the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate[3,4]. On 2 December 2022, Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream, obtaining an exclusive license to develop, register and commercialize the product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the product in the Territory. Dermavon has sublicensed the relevant rights for the product outside of Mainland China to the Group (excluding Dermavon). About CMS CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value. CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network. CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development. References 1. China Insights Consultancy’s industrial report 2. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib 3. The EMA approval information for vitiligo indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 4. The EMA approval information for AD indication can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/opzelurar-ruxolitinib-cream-becomes-first-steroid-free-topical CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: [email protected] Website: https://web.cms.net.cn/en/home/
  8. FinanceKincora Announces Exploration Strategy Update: Drilling Planned Across Four ProjectsMELBOURNE, Sept 4, 2026 - Copper-gold explorer and hybrid prospect generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to provide an update on planned sole funded exploration over the upcoming Spring and Summer field season including over 25,000 metres of air-core drilling across four projects in Central West NSW, Australia. The programs align with the Company's hybrid prospect generator model, under which partners fund the majority of exploration expenditure with Kincora generating large-scale porphyry system targets. The air-core programs complement ongoing asset-level partner discussions and are expected to add scale and value while upgrading Kincora's geological concepts. HIGHLIGHTS Sole funded budget of up to A$3-million Board approval for extensive air-core drilling seeking to systematically and cost effectively advance 17 targets across four projects (Nyngan West, Fairholme, Cowal East and Trundle) expanding existing known mineralised porphyry systems and testing of new targets. Formal process with potential new asset level partners progressing with strong interest. Kincora's net cash position is forecast to further increase in both September and the December quarter with further receipt of proceeds from the US$10-million divestment of our Mongolian projects 1. Kincora's last reported cash balance was A$12-million 2. Programs for 340 holes and over 25,000 metres Nyngan West: Maiden drilling across both ultramafic and Macquarie Arc porphyry targets. Fairholme: Seeking to expand a structurally controlled gold system at the Gateway target from a 1.6km to 2.6km strike, advance the adjacent Dungarvan target and expand three porphyry copper system targets in the northern portion of the license. Maiden drilling proposed across the strategically located southern Nerang target. Cowal East: Series of drill lines across six targets stepping out from two known intrusive systems and maiden drilling of regionally significant geophysical anomalies. Trundle: Very shallow drilling across a total of 19km2 area in the north, south and Dunns section of the project seeking to replicate the success of similar programs at the Northparkes project that have led to multiple porphyry copper-gold deposit discoveries situated within the same interpreted caldera. Condobolin update: Full assay results pending for the completed 9-hole, 2,615 metre program with localised higher-grade gold and base metals 3. Independent review proposed to confirm interpretation of a Reduced Intrusion System geological target model and refine follow up. New opportunities: Kincora continues to review a pipeline of new opportunities where it has a competitive advantage to add shareholder value including recent claim extensions of targets at the Fairholme and Cowal East projects. The Company is proactively utilising Geomorphic AI's proprietary system in the review process with thirty reviews undertaken to date 4. President & CEO, Sam Spring, commented: "We are excited to embark on an extensive air-core drilling program over the upcoming Spring and Summer field season, systematically advancing four key projects across our NSW portfolio. Our projects and targets compete for capital and resourcing. These programs are designed to quickly and cost effectively test and advance our geological concepts, add scale and value, and position the highest-priority opportunities for larger-scale exploration. Importantly, this work complements our hybrid prospect generator strategy. Following extensive independent, internal and next-generation technical reviews, we have commenced a formal process with potential new asset-level partners for a number of our more advanced and brownfield porphyry projects with strong initial interest. The planned sole funded drilling programs will complement this process. With partner-funded drilling by AngloGold Ashanti continuing, management fee income being generated and further proceeds expected from the US$10-million divestment of our Mongolian portfolio, Kincora is well positioned to fund these programs while continuing to grow our net cash position and pursue new growth opportunities." Figure 1: Kincora's NSW Project Portfolio Eight projects in total, including the Northern Junee Narromine Belt project funded by and in partnership with AngloGold Ashanti where drilling is ongoing. Recent diamond drilling has taken place at the Condobolin project, results pending, with air-core drilling proposed at the Nyngan West, Fairholme, Cowal East and Trundle projects. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/2305/312600_795de1173497999c_001full.jpg STRATEGY AND PROJECT OVERVIEW As part of Kincora's ongoing portfolio review process, the Company's Technical Committee has evaluated the exploration and corporate strategy for each of its wholly owned NSW projects, with a focus on systematically advancing opportunities and generating shareholder value. These reviews consider both technical and commercial factors in-line with the Company's hybrid prospector generator model, under which the majority of exploration expenditure is funded by asset level partners. Kincora's role is to secure prospective ground and undertake earlier stage, lower cost exploration activities to advance and validate geological concepts ahead of larger-scale drilling programs. Recent internal and independent reviews across the portfolio have identified significant open and highly prospective areas within various wholly owned projects where extensions of mineralisation and/or open geophysical anomalies currently lack sufficient coverage to support deeper drilling. All targets and projects are ranked and compete for capital and resources, taking into account technical merit and operational considerations. From this process 17 targets have been prioritised for drilling during the upcoming Spring and Summer field season, when ground conditions and access are generally favourable for air-core drilling. As discussions with potential partners advance around earn-in and joint venture funding models capable of supporting multi-year, multi-phase drilling, Kincora has also pegged open ground adjacent to priority targets at the Cowal East and Fairholme projects. The Company is now seeking to sole fund over 25,000 metres of air-core drilling at four projects. These programs are in addition to ongoing partner-funded drilling with AngloGold Ashanti, which has been underway since the 2025 end of year holiday break. Air-core drilling is a fast and cost-effective technique for collecting basement samples under shallow cover to test and refine target areas mapping mineralisation, alteration, lithology and depth. These results help generate, test and refine targets and this technique has been a key phase in many significant discoveries in the Lachlan Fold Belt. The spacing of Kincora's programs are reflective of the nature of the target, stage of exploration at the target and seeking to gain coverage over significant geophysical anomalies to help refine and determine where more detailed and expensive drilling is warranted. NYNGAN WEST PROJECT The Nyngan West project includes a single large licence (207.4km2) with no outcrop and has not previously been drill tested or basement rocks sampled. The project is prospective for two different mineral systems and is located to the immediate west of the Company's Nyngan project which is included in an earn-in and joint venture agreement with AngloGold Ashanti where drilling is ongoing testing maiden porphyry system targets. The program at Nyngan West is expected to be completed before year end. Sole funded Kincora drilling will test two porphyry targets for potential extensions of the Junee-Narromine Belt of the Macquarie Arc under relatively shallow interpreted cover. Drilling is also proposed to test a regionally significant magnetic high, gravity low anomaly and structurally controlled extensions interpreted to be part of the Fifield Suite. These targets are highly prospective for various critical minerals including scandium, nickel and cobalt, which are often hosted on similar magnetic highs to the west of the Junee-Narromine Belt. Such settings host Sunrise Energy Metals Limited's (SRL.ASX, market capitalisation A$2.9-billion) namesake project and adjacent ground to Nyngan West. FAIRHOLME PROJECT Previous drilling by major mining companies, predominately Newcrest, has defined an extensive structurally controlled gold with base metals mineralised footprint in the south of the project at the Gateway target and several earlier stage porphyry copper targets to the north. Previous exploration predominately focused on a traditional Macquarie Arc porphyry copper deposit model rather than the recent Cowal-style epithermal gold and/or hybrid porphyry copper-gold methodology, often off the shoulders of such geophysical anomalies and with greater weighting on geochemical vectors and structure. This newer exploration model has resulted in significant recent exploration success in the Macquarie Arc by Evolution Mining at the Cowal mine, Alkane Resources at Boda-Kaiser deposit, Waratah Minerals at Spur discovery and LinQ Minerals at the Dam/Gidginbung projects. Koonenberry Gold is shortly planning sole funded drilling at its Wilga project west of Kincora's Fairholme project (and noting Newmont is earning into Koonenberry Gold's Fairholme project immediately adjacent to the north of our Fairholme project). Initial air-core and diamond drilling by Kincora has already expanded the structurally controlled gold and base metals system at the Gateway target from 600 metres to 1,600 metres 5 with the proposed program seeking to expand this a further kilometre, as well as advance the adjacent Dungarvan target. Follow up step out drilling is also proposed at three highly prospective porphyry copper targets in the northern portion of the licence, Anomaly 2, Driftway C and Manna Creek. Land access and maiden drilling are proposed across the strategically located southern Nerang prospect. Drilling at Fairholme is expected to commence immediately after the Christmas-New Year break. COWAL EAST PROJECT Previously the focus of limited drilling by BHP and Newcrest, the Cowal East project sits immediately to the east, on the other side of Lake Cowal to Evolution Mining's flagship Cowal mine and as close as 4km north of the Marsden porphyry copper-gold deposit. Like other projects on the Cowal Igneous Complex, there is limited outcrop with basement masked by relatively shallow post mineral cover. Earlier in 2026, Kincora completed a 'traditional' ground gravity survey which upgraded various targets 6, with Atomionics Pte Ltd's next generation 'quantum" gravity survey scheduled to commence in November. Kincora has designed a series of drill lines across six targets stepping out from two known Macquarie Arc intrusive complexes and maiden drilling of regionally significant geophysical anomalies testing similar targets and settings that led to the discovery of Marsden. TRUNDLE PROJECT Kincora's Trundle project is hosted in the interpreted western rift of the Northparkes Igneous Complex and with previous drilling predominately by the major mining companies returning large mineralised footprints at/near surface in the north and south of the licence 7. Recently completed internal and independent reviews have identified multiple prospective and open mineralised intrusion centres, seeking to test more optimal interplays of structures occurring along prospective zones characterised by strong gradients. Very shallow drilling across a total of 19km2 area in the north, south and Dunns section of the project is seeking to replicate the success of similar programs at the Northparkes mine and other side of the same interpreted caldera that have led to multiple porphyry copper-gold deposit discoveries, including the E44 deposit which is currently the focus of a multiple rig program and potentially the first satellite deposit to the existing mill. MARKETING ENGAGEMENT The Company announces that it has entered into a marketing services agreement with Resource Stock Digest (RSD), a resource-sector investor media and marketing company based out of Texas, U.S.A., effective September 2nd, 2026, pursuant to which, among other things, RSD has agreed to provide certain promotional services to the Company in accordance with TSX Venture Exchange (the Exchange) Policy 3.4 - Investor Relations, Promotional and Market-Making Activities. RSD has been engaged for a 2-month advertising and marketing program for total cash consideration of USD $75,000, which will be funded from the Company's general working capital as a single payment in September. RSD conducts interviews with the Company and produces content that is distributed to RSD's subscriber base and connects issuers to the investment community across North America. There are no performance factors contained in the agreement, and RSD will not receive securities of the Company as compensation. RSD is arm's length from the Company and has no direct interest in the Company or its securities nor any right or intent to acquire such an interest. The agreement is subject to the approval of the Exchange. RSD is owned and operated by Gerardo Del Real and Nick Hodge and its contact details are as follows: Gerardo Del Real, 2250 Double Creek Dr #5669, Round Rock, TX 78665, USA; Email: [email protected]. FOR FURTHER INFORMATION PLEASE CONTACT: Sam Spring, President and Chief Executive Officer [email protected] or +61431 329 345 Kaitlin Taylor, Investor Relations [email protected] Executive office 400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Subsidiary office Australia C/- JM Corporate Services Level 6, 350 Collins Street Melbourne, VIC, Australia 3000 About Kincora Kincora Copper Limited (ASX: KCC) (TSXV: KCC) is an emerging Australia-focused gold-copper explorer with a hybrid project generator strategy. The Company is successfully proving up the prospectivity of its extensive project portfolio, which includes multiple district-scale landholdings and scalable drill ready targets. These assets are located in Australia's Lachlan Fold Belt, one of the globe's leading porphyry belts, and the historical Condobolin mining field within the Cobar basin in NSW. The Company has already unlocked over A$100 million of potential partner funding for multiple earlier stage and/or non-core porphyry projects. These initial deals have supported over 20,000 metres of drilling and over A$10m of partner funded exploration since late 2024, with management fees and exploration ramping up. Various partner discussions are ongoing for its remaining 100% owned flagship and advanced exploration stage porphyry projects. By having a significant portfolio of partner funded large porphyry projects, and very focused capital efficient programs at our other sole funded projects, the Company is seeking to position Kincora as a leading institutional grade explorer in the public Australian and Canadian markets, and the leading project generator on the ASX. The Company's website is: www.kincoracopper.com. This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763) References: Kincora is not aware of any new information or data that materially affects the information as disclosed to the originally sighted references: 1 Mongolian projects: Kincora press releases "Kincora receives payment for Mongolian Asset divestment" (May 19, 2026), "Kincora executes agreements for Mongolian Asset divestment" (July 2, 2026), and "Kincora quarterly report for the period ended June 2026" (August 14, 2026) 2 Last reported cash balance: Kincora press release "Kincora quarterly report for the period ended June 2026" (August 14, 2026) 3 Condobolin project: Kincora press releases "Kincora commences drilling at historic Condobolin Mining field" (April 28, 2026) and "Kincora quarterly report for the period ended June 2026" (August 14, 2026) 4 Geomorphic AI: Kincora press releases "Kincora engages Geomorphic AI" (April 29, 2026) and "Kincora quarterly report for the period ended June 2026" (August 14, 2026) 5 Fairholme project: Kincora press releases "First phase drilling results and commencement of phase two at the Fairholme project" (March 31, 2022), and "Kincora quarterly report for the period ended June 2026" (August 14, 2026) 6 Cowal East project: Kincora press releases "Kincora consolidates, commences Geophysics at Cowal East" (March 10, 2026), and "Kincora quarterly report for the period ended June 2026" (August 14, 2026) 7 Trundle project: Kincora press releases "Positive assay results for the Trundle and Fairholme projects" (August 18, 2022), and "Kincora quarterly report for the period ended June 2026" (August 14, 2026) Third party information: Koonenberry Gold Limited - disclosures regarding the Newmont Exploration Pty Ltd earn-in over the Fairholme Copper-Gold JV Project and planned drilling at the Wilga project. Waratah Minerals Limited - disclosures regarding the Spur project and the Cargo Intrusive Complex. Evolution Mining Limited - disclosures regarding the Cowal mine and the Northparkes mine, including the E44 deposit. Alkane Resources Limited - disclosures regarding the Boda-Kaiser project. LinQ Minerals - disclosures regarding the Dam and Gidginbung projects. Sunrise Energy Metals Limited - Sunrise project disclosures; market capitalisation sourced from ASX market data as at close of business September 1st, 2026. Kincora has not independently verified the third-party information referred to above, and it is not to be regarded as being reported, adopted or endorsed by Kincora. Qualified Person The scientific and technical information in this announcement was prepared in accordance with the standards of the Canadian Institute of Mining, Metallurgy and Petroleum and National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and was reviewed, verified and compiled by Kincora's staff under the supervision of Peter Leaman (M.Sc. Mineral Exploration, FAusIMM), Senior Vice-President of Exploration of Kincora, and John Holliday (BSc Hons, BEc, member of the Australian Institute of Geoscientists), Non-Executive Director and Chairman of Kincora's Technical Committee, who are Qualified Persons for the purpose of NI 43-101. JORC Competent Person Statement Information in this announcement that relates to Exploration Results or Mineral Resources are those that have been previously reported (with the original release referred to in this announcement), and have been reviewed and approved by John Holliday and Peter Leaman, who are Competent Persons under the definition established by JORC and have sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. John Holliday and Peter Leaman consent to the inclusion in this report of the matters based on their information in the form and context in which it appears. The review and verification process for the information disclosed herein for the projects referred to in this announcement have included the receipt of all material exploration data, results and sampling procedures of previous operators and review of such information by Kincora's geological staff using standard verification procedures. This announcement refers to historical exploration results, including drilling completed by Newcrest, BHP and other previous operators. Kincora has not independently verified this historical and third-party information, it is not to be regarded as being reported, adopted or endorsed by Kincora, and a Competent Person has not done sufficient work to classify the historical exploration results as Mineral Resources in accordance with the JORC Code. It is uncertain that further exploration will result in the determination of Mineral Resources or Ore Reserves. Kincora is not aware of any new information or data that materially affects the information referred to in respect of any historical estimates and confirms that all material assumptions and technical parameters underpinning those estimates continue to apply and have not materially changed. Forward-Looking Statements Certain information regarding Kincora contained herein may constitute forward-looking statements and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking information"). Forward-looking information is generally identifiable by the use of words "believes", "may", "plans", "will", "anticipates", "intends", "could", "estimates", "expects", "forecasts", "projects", and similar expressions, and the negative of such expressions. Such forward-looking statements or information include but are not limited to statements or information with respect to the planned exploration programs, drilling metres, hole counts, pending assay results, proposed independent reviews, budgets, review and potential pursuit of new opportunities, including the use and anticipated benefits of Geomorphic AI, the Company's forecast net cash position, expected receipt of funds relating to the announced divestment of the Mongolian projects and timing described in this announcement, the outcome of partner discussions, anticipated partner-funded exploration activities, and the marketing services agreement with Resource Stock Digest. Forward-looking statements may include estimates, plans, milestones, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Readers are cautioned not to place undue reliance on forward-looking information and statements. Forward-looking information and statements are based on the then current expectations, beliefs, assumptions, estimates and forecasts about the Company's business and the industry and markets in which it operates. Forward-looking information and statements are made based upon numerous assumptions, including, among other things, the Company's ability to obtain and maintain necessary land access, permits and approvals; favourable weather and ground conditions; the availability of drilling rigs, personnel, contractors, equipment and laboratory capacity; the availability of sufficient funding; the receipt and timing of remaining proceeds from the Mongolian project divestment; the costs and timing of the planned exploration programs; the performance of counterparties under existing agreements; the continuation of partner-funded exploration activities and management fee arrangements; the willingness of prospective partners to enter into earn-in, joint venture or other asset-level arrangements; and general economic, market, regulatory and business conditions. Forward-looking information involves numerous risks and uncertainties, including risks that planned exploration programs may be delayed, modified, reduced or not completed; that drilling or geophysical surveys may not produce results consistent with the Company's geological interpretations or objectives; that assay results may not confirm preliminary interpretations; that anticipated proceeds from the Mongolian project divestment may not be received in the amounts or within the timelines anticipated; that the Company's net cash position may not increase as forecast; that asset-level partner discussions may not result in definitive agreements, partner funding, exploration expenditures or management fee income; and that the Resource Stock Digest agreement may not receive Exchange approval or be performed as contemplated; risks associated with weather conditions, rig availability, access, resourcing, permitting, jurisdictional matters, counterparties, government approval, ESG, and general market and business conditions; and other factors, and actual results might differ materially from results suggested in any forward-looking information. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations, geological concepts and plans will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: market prices; approvals; continued availability of capital and financing and general economic; market or business conditions; counterparty risk; sovereign risk; and investor sentiment. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.
  9. Sustainability“可持续锂电池行业工作组”今日启动！新能源电池强势反弹，机构重申本轮锂电涨价周期今日（9月3日），新能源电池板块表现活跃，聚焦储能的新能源电池ETF华宝（159071）标的指数上涨1.86%。指数50只成份股中35涨13跌2平，其中 同飞股份 涨超9%， 麦格米特 涨超7%，禾望电器涨超6%， 申菱环境 、 金盘科技 涨超5%。 消息面上，据财联社报道，在今日举行的第四届零碳协同创新大会期间，由 天齐锂业 牵头组建、覆盖锂电池全价值链的“可持续锂电池行业工作组”正式启动。这是中国锂电池行业首个覆盖上中下游全链条的ESG与可持续发展行业协作机制，目前已汇聚了锂电全价值链代表企业二十余家。 华泰证券 指出，9月锂电产业链五大环节排产均创年内新高，国内储能招中标与装机同步回暖，欧洲汽车电动化持续提速，8月锂电各环节涨价范围较7月进一步扩大。重申看好本轮锂电涨价周期，同时看好钠电池从1到N的产业趋势以及固态电池新技术产业化。 板块估值方面，新能源电池ETF华宝（159071）标的指数最新PE估值约22倍，位于近3年
  10. SustainabilitySAPWhen Sustainability Data Meets Finance-Grade Rigor: Winning Under IFRS S1 and S2Companies: SAPTrusted sustainability data is becoming one of the most valuable assets an enterprise holds.
  11. Biotech & pharmaChiesi GroupChiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are ValidatedPARMA, Italy, September 03, 2026--Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a further step in its Carbon Minimal Inhaler (CMI) journey with the validation of regulatory submissions in Europe for its SITT and ICS/LABA pMDIs.
  12. SustainabilityConcrete Admixtures Market Size to Skyrocket USD 44.50 Billion by 2035 Growing at 7.8% CAGR | SNS InsiderU.S. Concrete Admixtures Market to Reach USD 6.75 Billion by 2035; Europe to Grow to USD 8.60 Billion Amid Sustainable Construction Demand